Thank you, Reade. And good morning, everyone. As we discussed, we are pleased with our third quarter performance in the ongoing progress we were making on our strategic initiatives where the third quarter net revenue increased 6.6% compared to the prior year, driven by adjusted comparable store sales growth and growth for new store sales. The timing of unearned revenue negatively impacted revenue in the period by 30 basis points. We opened 70 new America’s Best and for Eyeglass World stores in the third quarter. Unit growth in our America’s Best in Eyeglass World brands increased 5.3% on a combined basis over the total store base last year, and we ended the quarter with 1402 stores. As Reade mentioned, we are still on track to open between 65 stores and 70 stores in 2023. Consistent with our previous guidance. Adjusted comparable store sales grew 4.3% compared to the third quarter of 2022 driven by an increase in customer transactions into a lesser degree and increase in average ticket. As Reade mentioned, we saw strength particularly in America’s Best, which was partially offset by softness in our Eyeglass World business. As Reade discussed, our initiatives continue to address our dark and dim store population. Well we have always contended with dark and dim stores. However, the combination of post COVID doctor availability issues and a more challenged lower end consumer has exacerbated the impact of dark and dim on our revenue performance. On average, a dark store is approximately 80% less productive than a store with full coverage, which we define as having five to six days of in store doctor coverage. A dim store on average is approximately 50% less productive than a store with full coverage. By enabling remote we have significantly improved this productivity drag and while there is still more progress to be made. We are making nice headway with dark and dim stores. As a percentage of net revenue costs applicable to revenue increased 70 basis points compared with the prior year quarter driven primarily by the deleverage of optometrists related costs, as well as other components of service revenue, including warranty play revenue. These costs were partially offset by ongoing strength in exam revenue and a decrease in product costs attributable to higher eyeglass margin and decreased freight expenses. As we discussed last quarter, the pricing actions taken with respect to exam has helped to partially mitigate the increase in optometrist related costs. For the quarter, the net impact from deleverages of optometrists related costs and the increase in exam revenue was approximately 50 basis points. Adjusted SG&A expense as a percentage of revenue increased 90 basis points compared with a third quarter of 2022. The increase in adjusted SG&A as a percentage of net revenue was primarily driven by performance-based incentive compensation, as we expected. Depreciation and amortization expense was $24.4 million, compared to $24.9 million in the prior year period. Adjusted operating income was $15.7 million, compared to $21.5 million in the prior year period. Adjusted operating margin decreased 130 basis points to 3%, due primarily to the same factors I just reviewed. Net interest expense was $3.7 million dollars, which includes mark-to-market gains and losses on derivative instruments, and changes related to amortization of debt discount and deferred financing costs of $3.5 million. The year-over-year change was primarily a result of lower derivative income and higher interest expense on our term loan partially offset by higher income on cash balances. Our effective tax rate in third quarter was 5.8%, primarily due to legacy segment impairment losses. We expect our tax rate on ordinary income items be in line with our original guidance. Adjusted diluted EPS was $0.15 per share compared to $0.15 per share in the prior year period. Turning to our financial results for the nine months to date, as compared with the prior year period, net revenue increased approximately 5% driven by new stores and adjusted comparable store sales growth of 2%. Adjusted operating margin declined 180 basis points compared to the prior year period, driven primarily by the same factors I just reviewed, which impacted the third quarter. Please note our adjusted results for the third quarter in nine months year-to-date period exclude the impact associated with one-time charges related to the termination of our Walmart partnership, including $2 million in retention bonuses and termination benefits for certain employees supporting the Walmart Vision centers, and the AC Lens distribution center and $79.4 million of non-cash impairment charges related to impairment of goodwill, intangible assets and fixed assets. Turning next to our balance sheet, we ended the quarter with a cash balance of approximately $266 million and total liquidity of $559 million, including available capacity from our revolving credit facility. As of September 30th, our total debt outstanding was $563 million. And for the trailing 12 months we ended the period with net debt to adjusted EBITDA of 1.9 times. Year-to-date, we generated operating cash flow of $153 million. In addition, the first nine months of fiscal 2023, we invested $82 million in capital expenditures, primarily driven by investments in new stores, our labs and distribution center and our remote medicine technology. We remain on track for capital expenditures to be in the range of $115 million to $120 million in 2023 to support our key growth initiatives. Our balance sheet and liquidity remained strong, enabling our robust and disciplined capital allocation plan, which is designed for continued growth balanced with opportunistically returning capital to our shareholders. Earlier this summer, we refinanced our term loan A and extended our revolving credit facility and we are continuing to evaluate options with respect to our convertible note which mature in May of 2025. Given the current environment and our focus on continuing to fortify our balance sheet, our share repurchase activity to date was focused on the first quarter of this year. And as of the end of Q3, we have $25 million of share repurchase authorization remaining. We will continue to deploy capital to ensure we are making prudent decisions that are financially responsible for the company. Moving now to the discussion of our 2023 outlook, year-to-date, we remain on track with our expectations for this year. And as we move into the fourth quarter, our seasonally lowest quarter, from a profitability perspective, we are narrowing our full year guidance range. We now expect revenue to be in the range of $2.115 billion to $2.125 billion supported by adjusted comparable store sales growth of approximately 2% for fiscal 2023. Our revenue guidance incorporates ongoing execution of our strategic initiatives focused on expanding exam capacity and contemplates current business trends. We continue to expect depreciation and amortization to be in the range of $99 million to $101 million. We expect adjusted operating income and adjusted diluted EPS to be in the range of $60 million to $65 million to $0.53 to $0.58 per share, respectively. Our guidance for adjusted diluted EPS as soon as approximately $78 million weighted average diluted shares outstanding. As a reminder, our adjusted results as well as our outlook excludes the one-time charges related to the termination of our Walmart partnership I reviewed as well as the expected costs associated with the first phase of our ERP implementation. Regarding our ERP project, as Reade noted, we are taking a disciplined and phased approach. The first phase which kicked off late in third quarter, we'll focus primarily on finance system upgrades, it is expected to be substantially complete in 2024. We expect to incur one-time expenses associated with the first phase of this project to be between $11 million is $13 million of which we expect to incur between $2 million and $3 million in fiscal 2023. Now, let me provide an update on the work underway as we plan for the upcoming termination of our Walmart partnership. As we previously announced, as of February 23rd, 2024, we will transition the operations of the 229 Vision Centers, as well as the related optometric services for Walmart in California to Walmart. And as of Jun 30, 2024, we will see the wholesale distribution and ecommerce contact lens services that we provide to Walmart and Sam's Club through our AC Lens business. And we'll wind down the remaining AC Lens operations. For fiscal 2023, we expect our Walmart store operations and the wholesale distribution and related services to Walmart and Sam's Club included in our corporate other segments to account for approximately $355 million of revenue. The remaining portion of our AC Lens operations, which generates approximately $45 million in sales and immaterial from an earnings perspective will be wound down in conjunction with the overall Walmart and Sam's Club exit. Combined, the Walmart store operations in the AC Lens operations are expected to generate approximately $400 million in revenue and earnings before income tax of approximately $15 million. The annualized direct and indirect costs associated with these operations for fiscal 2023 are expected to be approximately $385 million. We expect costs associated with these operations, including our Ohio distribution center to be wound down in conjunction with the contract termination date. While we expect to provide our full 2024 outlook as part of our year-end earnings call in 2024. Due to the Walmart contracts staggered end date in 2024. We want to provide some additional details now to help with modeling. Using 2023 as our guide, we expect revenue related to the Vision Center Operations and the AC Lens operations in fiscal 2024 to range between $140 million to $150 million with a margin profile similar to 2023. Assuming no material degradation in the Walmart operation. As we look ahead, with an enhanced focus on our largest growth brands, we are taking actions that will further optimize our cost structure and position us to advance our long-term strategy and strengthen our competitive position. As Reade noted, beginning in 2024, we will be implementing an expense reduction program, targeting annualized savings of $10 million to $12 million focused on streamlining corporate overhead as well as reducing travel expenses in third party spend. As Reade noted, we are also planning to take additional non headline pricing actions, which we believe will continue to enable us to deliver on our mission to provide affordable eye care and eyewear while maintaining a competitive position in the marketplace, and leveraging our costs more effectively. We expect the combined impact of the non-headline pricing increases in the cost savings program to more than offset the profitability gap created by the termination of the Walmart partnership. We believe these actions combined with gross margin tailwind from the exit of the lower margin Walmart operations. And the ongoing progress of our strategic initiatives, including the completion of the large initial implementation phase of our remote and EHR capabilities. Position as well to return to mid-single digit adjusted comparable store sales growth and operating margin by fiscal 2025. In summary, we are pleased with ongoing progress and expanding exam capacity and expect to continue to build on this momentum as we move forward with an even greater focus on our strategic growth brands. We believe the actions we have announced today will further support our plans to drive long term success and shareholder value. Thank you for your time today. I will now turn the call over to Reade for closing remarks before we open the call for your questions. Reade.